



Procuring with Integrity

+264 (61) 447 700 pr@cpb.org.na www.cpb.org.na PO Box 23650 Mandume Park, 1 Touart Street, Windhoek, Namibia

AWARD OF PROCUREMENT CONTRACT

NOTICE IN TERMS OF SECTION 55(8) OF THE PUBLIC PROCUREMENT ACT, 15 OF 2015

TO ALL BIDDERS:

**RE: SUPPLY AND DELIVERY OF ANTI-RETROVIRAL MEDICINE (ARVS) PRODUCTS:
(PROCUREMENT REFERENCE NO. G/OIB/CPBN-03/2020)**

Pursuant to section 55(8) of the Public Procurement Act, 15 of 2015 and in line with ITB 40 of the Bid Document of the above-referenced bid, this Notice serve to notify all bidders who submitted bids for this bid, that following the evaluation process, the contract has been awarded to:

- **Africure Pharmaceuticals Namibia to the value of N\$361,820,222.23 (Including VAT, DDP-CMS).**
- **Nampharm (PTY) LTD to the value of N\$3,640,520.27 (Including VAT, DDP-CMS).**

The contract will be for a period of 12 months (1 year).

For more details, please log on to: www.cpb.org.na

31 May 2021



**P.P. Swartz
CHAIRPERSON**



RECEIPT ACKNOWLEDGMENT FORM

**SUPPLY AND DELIVERY OF ANTI-RETROVIRAL MEDICINE (ARVS) PRODUCTS:
(PROCUREMENT REFERENCE NO. G/OIB/CPBN-03/2020)**

I/we _____
_____ herewith acknowledge receipt of the attached Procurement Award
dated _____ and undertake to immediately return it to CPBN as
proof of receipt.

Name: _____

Signature: _____

Date: _____

Company Stamp: _____



Procuring with Integrity

+264 (61) 447 700 pr@cpb.org.na www.cpb.org.na P.O. Box 23650 Mandume Park, 1 Teinert Street, Windhoek, Namibia

EXECUTIVE SUMMARY OF BID EVALUATION REPORT

PROJECT TITLE: SUPPLY AND DELIVERY OF ANTI-RETROVIRAL MEDICINE (ARV) PRODUCTS

REFERENCE NUMBER OF PROCUREMENT: G/OIB/CPBN-03/2020

1. Scope of Contract: Supply and Delivery of Anti-Retroviral Medicine (ARV) Products
2. Procurement method used: Open International Bidding
3. Date of Invitation of Bids: 28 September 2020
4. Closing date for submission of bids: 14 December 2020
5. Date and place of opening of bids: 14 December 2020 at CPBN
6. Number of bids received by closing date: Eighteen (18)
7. Responsiveness of bids

Bidder No.	Name of the Bidder(s)	Pricing at Bid Opening N\$/VAT Excl	Responsive or not responsive (Yes/ No)	Reasons why bid is not responsive: More details are on www.cpb.org.na
4	Cospharm Investments (Pty) Ltd	303,847,422.62 (VAT Inclusive)	No	<ul style="list-style-type: none"> Conflict of interest in terms of ITB 5.4(d) on page 10 of the Bidding document.
7	Mylan Laboratories Ltd	297,090,904.10	No	<ul style="list-style-type: none"> Conflict of interest in terms of ITB 5.4(d) on page 10 of the Bidding document.
10	Aurobindo Pharma (Pty) Ltd	189,017,230.40	No	<ul style="list-style-type: none"> The Bidder did not submit Founding statement in accordance to criteria 2.1.1. Bidder did not initial the Bid Form as required in criteria 2.1.2. The Bid Forms submitted differs from that of form 5 in section VII on page 77-79 of the bidding document contrary to ITB 15.1, qualification criteria 2.1.2 and ITB 22.4.
16	Laurus Labs Limited	229,672,030.50	No	<ul style="list-style-type: none"> Conflict of interest in terms of ITB 5.4(d) on page 10 of the Bidding document.
18	Windhoek Medical Solutions	265,005,277.90	No	<ul style="list-style-type: none"> Conflict of interest in terms of ITB 5.4(d) on page 10 of the Bidding document.
1	Broad Pharma (Pty) Ltd	285,234,814.31	No	<ul style="list-style-type: none"> The Bidder failed to submit product registration letter with NMRC or Authorization letter from NMRC to supply unregistered products, which was a mandatory requirement in terms of criteria 2.1.6 in the SBD.
3	Geka Pharma (Pty) Ltd	277,722,201.35	No	<ul style="list-style-type: none"> The Bid Form submitted differs from that of form 5 in section VII on page 77-79 of the SBD contrary to criteria 2.1.2 and ITB 22.4 in the SBD. Bidder did not initial page 4 of a letter in book 1 of 3 as required in evaluation criteria 2.1.2 on page 82 of the bidding document. The Bidder did not meet criteria 2.1.3 which is a requirement for

Bidder No.	Name of the Bidder(s)	Pricing at Bid Opening N\$/VAT Excl	Responsive or not responsive (Yes/ No)	Reasons why bid is not responsive: More details are on www.cpb.org.na
				<p>Mandatory Documents for Namibian Bidders only.</p> <ul style="list-style-type: none"> The Bidder did not meet criteria 2.1.6 on Page 84 of the Bidding document The Bidder did not meet Instruction to Bidder (ITB) 33.4 (a) under the Bidding Data Sheet .
9	Sun Pharmaceutical Industries Ltd	205,956.80	No	<ul style="list-style-type: none"> The Bidder failed to initial 10 pages in the annexures of World Health Organization (WHO), Agency Letter in terms of evaluation criteria 2.1.2 of the bidding document. The bidder did not meet the requirements of ITB 22.2 The bidder did not meet the requirements of ITB 15(1)(d) Written power of attorney as per clause 22.2. 2
11	Emcure Pharmaceutical Ltd.	USD14,411,903.90	No	<ul style="list-style-type: none"> The Bidder provided the bid price in USD 14,411,903.90. ITB Clause 18.1 (b).
12	Afrifarm Investment (Pty) Ltd.	83,953,298.86	No	<ul style="list-style-type: none"> The lease agreement submitted is not initialed by S. Hasselman who is given power of attorney signatory (authorised signatory) contrary to qualification criteria 2.1.2, ITB 22.2 and ITB 15.1(d) in the bidding document.
13	Strides Pharma Science Limited	212,205,390 (VAT Excl/Incl not indicated)	No	<ul style="list-style-type: none"> The attachments submitted contravenes ITB 22 (3).
14	Salutem Medicals (Pty) Ltd JV Green Enterprise Solutions	923,702,019.00	No	<ul style="list-style-type: none"> Power of attorney is not nominated by the JV and it was given for dealing with affairs of Namibia Defence Force (NDF) . The Bid Securing Declaration is not in the name of the JV and format is not compliant with ITB 20.1. Bidder not in compliance with ITB 20.3 of the bidding document.

Bidder No.	Name of the Bidder(s)	Pricing at Bid Opening N\$/VAT Excl	Responsive or not responsive (Yes/ No)	Reasons why bid is not responsive: More details are on www.cpb.org.na
				<ul style="list-style-type: none"> No Letter by the JV as per ITB 5.2 that states that "all partners shall be jointly and severally liable".
15	New Medical Investment Holdings (Pty) Ltd	314,725,727.29	No	<ul style="list-style-type: none"> Bidder not compliant with ITBs 20.1 and 20.3 of the bidding document.
17	Hetero Labs Limited	256,745,118.85	No	<ul style="list-style-type: none"> Hetero Labs Limited's entire bid submitted was not initialed by the authorised signatory contrary to ITB 22.2 and evaluation criteria 2.1.2 of the bidding document.
6	Cipla Quality Chemical Industries Limited	212,782,860.00	No	<ul style="list-style-type: none"> Item No. 11, the bid was responsive, however, the successful bidders had submitted the lowest substantial responsive bid compared to yours.
			No	<ul style="list-style-type: none"> Item No. 12, the bid was responsive, however, the successful Bidders had submitted the lowest substantial responsive bid compared to yours.
			No	<ul style="list-style-type: none"> Item No. 14, the bid was responsive, however, the successful Bidders had submitted the lowest substantial responsive bid compared to yours.
8	Supremo Pharmaceuticals (Pty) Ltd	243,237,285.06	No	<ul style="list-style-type: none"> Item No. 4, the bid was responsive, however, the successful Bidders had submitted the lowest substantial responsive bid compared to yours.
			No	<ul style="list-style-type: none"> Item No. 13, the bid was responsive, however, the successful Bidders had submitted the lowest substantial responsive bid compared to yours.
			No	<ul style="list-style-type: none"> Item No. 14, the bid was responsive, however, the successful Bidders had submitted the lowest substantial responsive bid compared to yours.
			No	<ul style="list-style-type: none"> Item No. 5 the requirements stipulated that the items should be



Bidder No.	Name of the Bidder(s)	Pricing at Bid Opening N\$/VAT Excl	Responsive or not responsive (Yes/ No)	Reasons why bid is not responsive: More details are on www.cpb.org.na
				tablet dispersible but the bidder offered tablets not dispersible contrary to ITB 33.3(c).
			No	<ul style="list-style-type: none"> Item No. 8 the requirements stipulated that the items should be tablet dispersible, but the bidder offered tablets not dispersible according to the WHO prequalified brand for Micro Labs which the bidder indicated as their brand contrary to ITB 33.3(c).
			No	<ul style="list-style-type: none"> Item No. 12 the bidder offered a product which is not a prequalified product according to the WHO prequalified list of products for Micro Labs which the bidder indicated as their brand contrary to ITB 33.3(c).
			No	<ul style="list-style-type: none"> Item No. 20 the requirements stipulated that the items should be oral granules, but the Bidder offered oral pellets contrary to ITB 33.3(c).
2	Nampharm (Pty) Ltd	49,219,355.80	No	<ul style="list-style-type: none"> Item No. 2 the requirements stipulated that the items should be 200mg Tablet, single scored, but the bidder offered capsules contrary to ITB 33.3(c).
			No	<ul style="list-style-type: none"> Item No. 16 the requirements stipulated that the items should be in 100 ml, but the bidder offered 200 ml contrary to ITB 33.3(c).
			Yes	<ul style="list-style-type: none"> Bidder not disqualified for items No. 3,6,17 and 18
5	Africure Pharmaceuticals Namibia	314,624,515.34	Yes	<ul style="list-style-type: none"> Bidder not disqualified

For more details on the reasons for disqualifications, please see the full Executive Summary on our website-www.cpb.org.na

8. Price comparison for bids that are substantially responsive:

Bidder Name	A. Price at Bid Opening N\$ (Excl. VAT)	B. Bid Price of awarded items after correction (N\$): (Incl. VAT, DDP-CMS)	C. Price after Margin of Preference [If applicable]	Ranking
Nampharm (Pty) Ltd	49,219,355.80	3,640,520.27	None	N/A
Africure Pharmaceuticals Namibia	314,624,515.34	361,820,222.23	None	N/A

9. Best Evaluated Bid:

- Nampharm (Pty) Ltd
- Africure Pharmaceuticals Namibia

31 May 2021



P.P. Swartz
Chairperson